Bosutinib is a second-generation ABL TKI approved for the treatment of CML-CP resistant and/or intolerant to prior therapy, as well as for newly diagnosed patients [4–6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.